Market for drugs from adult stem cells likely to grow, analyst says

06/17/2009 | CNNMoney

The U.S. gross sale of therapies based on adult stem cells is expected to reach more than $100 million this year, and it could climb to $8.2 billion by 2018, a market analyst said. Adult stem cells are more accessible, less expensive to test and less controversial than embryonic stem cells, and they have also been studied for the past 10 to 15 years, making them "ready for prime time," an expert said. Leading companies in the field include Osiris Therapeutics, StemCells, Cytori Therapeutics and Aastrom Biosciences.

View Full Article in:

CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX